{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:02:05Z","timestamp":1789570925687,"version":"build-2803163510"},"reference-count":351,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02766-8","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:13:15Z","timestamp":1786677195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies"],"prefix":"10.1186","volume":"25","author":[{"given":"Ming","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2766_CR1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/2159-8290.CD-24-1208","volume":"15","author":"J Pozniak","year":"2025","unstructured":"Pozniak J, Roda N, Landeloos E, Antoranz A, Van Herck Y, De Visscher A, et al. Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype. Cancer Discov. 2025;15:1819\u201334.","journal-title":"Cancer Discov"},{"key":"2766_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183366","author":"D Song","year":"2024","unstructured":"Song D, Wu Y, Li J, Liu J, Yi Z, Wang X, et al. Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI183366.","journal-title":"J Clin Invest"},{"key":"2766_CR3","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019;25:2021\u20133.","journal-title":"Clin Cancer Res"},{"key":"2766_CR4","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1038\/s41467-023-39035-x","volume":"14","author":"M Zhou","year":"2023","unstructured":"Zhou M, Wang J, Pan J, Wang H, Huang L, Hou B, et al. Nanovesicles loaded with a TGF-\u03b2 receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy. Nat Commun. 2023;14:3593.","journal-title":"Nat Commun"},{"key":"2766_CR5","doi-asserted-by":"publisher","first-page":"116443","DOI":"10.1016\/j.intimp.2026.116443","volume":"175","author":"X Gao","year":"2026","unstructured":"Gao X, Liu J, Deng D, Xiao J, Liu Y, Yan L, et al. The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer. Int Immunopharmacol. 2026;175:116443.","journal-title":"Int Immunopharmacol"},{"key":"2766_CR6","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378:eaba1624.","journal-title":"Science"},{"key":"2766_CR7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.ccell.2024.08.020","volume":"42","author":"Y Gao","year":"2024","unstructured":"Gao Y, Li J, Cheng W, Diao T, Liu H, Bo Y, et al. Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer Cell. 2024;42:1764-1783.e1710.","journal-title":"Cancer Cell"},{"key":"2766_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-026-10452-4","volume":"654","author":"W Zhang","year":"2026","unstructured":"Zhang W, Brown EL, Usmani A, Earland N, Kang M, Olelewe C, et al. Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature. 2026;654:1076\u201387.","journal-title":"Nature"},{"key":"2766_CR9","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s43018-025-01039-5","volume":"6","author":"Y Han","year":"2025","unstructured":"Han Y, Zhang L, Sun D, Cao G, Wang Y, Yue J, et al. Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity. Nat Cancer. 2025;6:1880\u201398.","journal-title":"Nat Cancer"},{"key":"2766_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","volume":"56","author":"AM Khaliq","year":"2024","unstructured":"Khaliq AM, Rajamohan M, Saeed O, Mansouri K, Adil A, Zhang C, et al. Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity. Nat Genet. 2024;56:2455\u201365.","journal-title":"Nat Genet"},{"key":"2766_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 2021;53:1334\u201347.","journal-title":"Nat Genet"},{"key":"2766_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, R\u00fcschoff JH, Moch H, de Souza N, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42:396-412.e395.","journal-title":"Cancer Cell"},{"key":"2766_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586\u201399.","journal-title":"Nat Biotechnol"},{"key":"2766_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41422-023-00831-1","volume":"33","author":"L Wu","year":"2023","unstructured":"Wu L, Yan J, Bai Y, Chen F, Zou X, Xu J, et al. An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte-tumor cell crosstalk, local immunosuppression and tumor progression. Cell Res. 2023;33:585\u2013603.","journal-title":"Cell Res"},{"key":"2766_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","volume":"29","author":"WC Hsieh","year":"2022","unstructured":"Hsieh WC, Budiarto BR, Wang YF, Lin CY, Gwo MC, So DK, et al. Spatial multi-omics analyses of the tumor immune microenvironment. J Biomed Sci. 2022;29:96.","journal-title":"J Biomed Sci"},{"key":"2766_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","volume":"24","author":"K Vandereyken","year":"2023","unstructured":"Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023;24:494\u2013515.","journal-title":"Nat Rev Genet"},{"key":"2766_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41580-024-00768-2","volume":"26","author":"GS Gulati","year":"2025","unstructured":"Gulati GS, D\u2019Silva JP, Liu Y, Wang L, Newman AM. Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics. Nat Rev Mol Cell Biol. 2025;26:11\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2766_CR18","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca BA, Steen CB, Matusiak M, Azizi A, Varma S, Zhu C, et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell. 2021;184:5482-5496.e5428.","journal-title":"Cell"},{"key":"2766_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39:1422-1437.e1410.","journal-title":"Cancer Cell"},{"key":"2766_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","volume":"14","author":"T Fu","year":"2021","unstructured":"Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14:98.","journal-title":"J Hematol Oncol"},{"key":"2766_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther"},{"key":"2766_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13:80.","journal-title":"Exp Hematol Oncol"},{"key":"2766_CR23","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1172\/JCI135528","volume":"130","author":"V Gauttier","year":"2020","unstructured":"Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, et al. Selective SIRP\u03b1 blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest. 2020;130:6109\u201323.","journal-title":"J Clin Invest"},{"key":"2766_CR24","doi-asserted-by":"crossref","unstructured":"Wan L, Li B, Ma T, Wang M, Xie F, Ge H, et al. An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma. J Immunother Cancer. 2026;14:e013959.","DOI":"10.1136\/jitc-2025-013959"},{"key":"2766_CR25","doi-asserted-by":"publisher","first-page":"1802194","DOI":"10.3389\/fimmu.2026.1802194","volume":"17","author":"Y Zeng","year":"2026","unstructured":"Zeng Y, Xiang Y, Chen L, Wen Y, Deng C, Huang X, et al. Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies. Front Immunol. 2026;17:1802194.","journal-title":"Front Immunol"},{"key":"2766_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920\u20138.","journal-title":"Nat Med"},{"key":"2766_CR27","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","volume":"14","author":"A Castiglioni","year":"2023","unstructured":"Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, et al. Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun. 2023;14:4703.","journal-title":"Nat Commun"},{"key":"2766_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"2766_CR29","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"2766_CR30","doi-asserted-by":"crossref","unstructured":"Ding D, Li W, Ren J, Li Y, Jiang G, Liang R, et al. SPP1(high) macrophage-induced T-cell stress promotes colon cancer liver metastasis through SPP1\/CD44\/PI3K\/AKT signaling. J Immunother Cancer. 2025;13:e012330.","DOI":"10.1136\/jitc-2025-012330"},{"key":"2766_CR31","doi-asserted-by":"publisher","first-page":"103977","DOI":"10.1016\/j.redox.2025.103977","volume":"89","author":"W Li","year":"2026","unstructured":"Li W, Tang Z, Xue J. Synergistic STING activation and oxidative cascades-induced ferroptosis drive tumor microenvironment remodeling by engineered manganese nanoreactors. Redox Biol. 2026;89:103977.","journal-title":"Redox Biol"},{"key":"2766_CR32","doi-asserted-by":"crossref","unstructured":"Monti M, Picinoli S, Bozzola A, Ferrari M, Bugatti M, Pezzali I, et al. Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas. J Immunother Cancer. 2026;14:e012222.","DOI":"10.1136\/jitc-2025-012222"},{"key":"2766_CR33","doi-asserted-by":"crossref","unstructured":"Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, et al. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023;11:e006773.","DOI":"10.1136\/jitc-2023-006773"},{"key":"2766_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2017","unstructured":"Jim\u00e9nez-S\u00e1nchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170:927-938.e920.","journal-title":"Cell"},{"key":"2766_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/2159-8290.CD-20-1274","volume":"11","author":"D Tavernari","year":"2021","unstructured":"Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, et al. Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. Cancer Discov. 2021;11:1490\u2013507.","journal-title":"Cancer Discov"},{"key":"2766_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41586-023-06132-2","volume":"618","author":"G Ortiz-Mu\u00f1oz","year":"2023","unstructured":"Ortiz-Mu\u00f1oz G, Brown M, Carbone CB, Pechuan-Jorge X, Rouilly V, Lindberg H, et al. In situ tumour arrays reveal early environmental control of cancer immunity. Nature. 2023;618:827\u201333.","journal-title":"Nature"},{"key":"2766_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"2766_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12:3.","journal-title":"Exp Hematol Oncol"},{"key":"2766_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s11864-023-01069-0","volume":"24","author":"V Geurts","year":"2023","unstructured":"Geurts V, Kok M. Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. Curr Treat Options Oncol. 2023;24:628\u201343.","journal-title":"Curr Treat Options Oncol"},{"key":"2766_CR40","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12:5668.","journal-title":"Nat Commun"},{"key":"2766_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, et al. Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021;14:146.","journal-title":"J Hematol Oncol"},{"key":"2766_CR42","doi-asserted-by":"publisher","first-page":"10045","DOI":"10.7150\/thno.106481","volume":"15","author":"VEA Laney","year":"2025","unstructured":"Laney VEA, Zhao W, Hwang IM, Hampson E, Dong J, Hall RC, et al. MR molecular imaging for monitoring and predicting tumor responses to immunotherapy. Theranostics. 2025;15:10045\u201363.","journal-title":"Theranostics"},{"key":"2766_CR43","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1038\/s41467-020-19408-2","volume":"11","author":"M Desbois","year":"2020","unstructured":"Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, D\u00fcrrbaum M, et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat Commun. 2020;11:5583.","journal-title":"Nat Commun"},{"key":"2766_CR44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"2766_CR45","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187:7492-7510.e7422.","journal-title":"Cell"},{"key":"2766_CR46","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12:4564\u201380.","journal-title":"Theranostics"},{"key":"2766_CR47","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324.","journal-title":"Br J Cancer"},{"key":"2766_CR48","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun. 2023;14:5110.","journal-title":"Nat Commun"},{"key":"2766_CR49","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984-997.e924.","journal-title":"Cell"},{"key":"2766_CR50","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"2766_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","volume":"19","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Marincola FM. Hypoxia and the phenomenon of immune exclusion. J Transl Med. 2021;19:9.","journal-title":"J Transl Med"},{"key":"2766_CR52","doi-asserted-by":"publisher","first-page":"e08451","DOI":"10.1002\/advs.202508451","volume":"12","author":"CH Hsu","year":"2025","unstructured":"Hsu CH, Chen J, Lee KJ, Donahue LR, Kacaj D, McDonough SP, et al. Therapy-induced ECM remodeling creates a transient immune barrier in residual melanoma. Adv Sci (Weinh). 2025;12:e08451.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR53","doi-asserted-by":"crossref","unstructured":"Horn LA, Chariou PL, Gameiro SR, Qin H, Iida M, Fousek K, et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-\u03b2 signaling enables PD-L1-mediated tumor eradication. J Clin Invest. 2022;132:e155148.","DOI":"10.1172\/JCI155148"},{"key":"2766_CR54","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41467-025-67967-z","volume":"17","author":"S Bai","year":"2025","unstructured":"Bai S, Chen M, Wang X, Lan N, Meng R, Yan Y, et al. GPR4 promotes immune exclusion in colon cancer through LOXL2-mediated extracellular matrix remodeling. Nat Commun. 2025;17:1196.","journal-title":"Nat Commun"},{"key":"2766_CR55","doi-asserted-by":"publisher","first-page":"1135456","DOI":"10.3389\/fonc.2023.1135456","volume":"13","author":"S Bruni","year":"2023","unstructured":"Bruni S, Mercogliano MF, Mauro FL, Cordo Russo RI, Schillaci R. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Front Oncol. 2023;13:1135456.","journal-title":"Front Oncol"},{"key":"2766_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.66505\/cbtt.v1i2.33","volume":"1","author":"L Wang","year":"2026","unstructured":"Wang L, Guo Y, Ma L, Miao K. Cancer cell-intrinsic programs that shape tumor immune ecosystems. Cancer Biome Target Ther. 2026;1:84\u2013118.","journal-title":"Cancer Biome Target Ther"},{"key":"2766_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"2766_CR58","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","volume":"8","author":"CS Grasso","year":"2018","unstructured":"Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730\u201349.","journal-title":"Cancer Discov"},{"key":"2766_CR59","doi-asserted-by":"publisher","first-page":"175883592091379","DOI":"10.1177\/1758835920913798","volume":"12","author":"DW Doo","year":"2020","unstructured":"Doo DW, Meza-Perez S, Londo\u00f1o AI, Goldsberry WN, Katre AA, Boone JD, et al. Inhibition of the Wnt\/\u03b2-catenin pathway enhances antitumor immunity in ovarian cancer. Ther Adv Med Oncol. 2020;12:1758835920913798.","journal-title":"Ther Adv Med Oncol"},{"key":"2766_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-015-0089-6","volume":"3","author":"S Spranger","year":"2015","unstructured":"Spranger S, Gajewski TF. A new paradigm for tumor immune escape: \u03b2-catenin-driven immune exclusion. J Immunother Cancer. 2015;3:43.","journal-title":"J Immunother Cancer"},{"key":"2766_CR61","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"2766_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.gastro.2023.04.032","volume":"165","author":"J Zhai","year":"2023","unstructured":"Zhai J, Chen H, Wong CC, Peng Y, Gou H, Zhang J, et al. ALKBH5 drives immune suppression via targeting AXIN2 to promote colorectal cancer and is a target for boosting immunotherapy. Gastroenterology. 2023;165:445\u201362.","journal-title":"Gastroenterology"},{"key":"2766_CR63","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/1535-7163.MCT-20-0825","volume":"20","author":"H Zhang","year":"2021","unstructured":"Zhang H, Bi Y, Wei Y, Liu J, Kuerban K, Ye L. Blocking Wnt\/\u03b2-catenin signal amplifies anti-PD-1 therapeutic efficacy by inhibiting tumor growth, migration, and promoting immune infiltration in glioblastomas. Mol Cancer Ther. 2021;20:1305\u201315.","journal-title":"Mol Cancer Ther"},{"key":"2766_CR64","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"2766_CR65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","volume":"38","author":"CS Grasso","year":"2020","unstructured":"Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, et al. Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38:500-515.e503.","journal-title":"Cancer Cell"},{"key":"2766_CR66","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397-404.e399.","journal-title":"Cell"},{"key":"2766_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7:188\u2013201.","journal-title":"Cancer Discov"},{"key":"2766_CR68","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329.","journal-title":"N Engl J Med"},{"key":"2766_CR69","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","volume":"12","author":"R Bao","year":"2020","unstructured":"Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12:90.","journal-title":"Genome Med"},{"key":"2766_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/HEP.0000000000001284","volume":"83","author":"T Taniai","year":"2026","unstructured":"Taniai T, Shimada S, Akiyama Y, Hatano M, Yasukawa K, Igarashi Y, et al. Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular HCC. Hepatology. 2026;83:231\u201348.","journal-title":"Hepatology"},{"key":"2766_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007567","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Newman S, Li A, Joy M, Lyons M, Pham MP, et al. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007567.","journal-title":"J Immunother Cancer"},{"key":"2766_CR72","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-24-0626","volume":"30","author":"S Scalera","year":"2024","unstructured":"Scalera S, Ricciuti B, Marinelli D, Mazzotta M, Cipriani L, Bon G, et al. Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy. Clin Cancer Res. 2024;30:4397\u2013411.","journal-title":"Clin Cancer Res"},{"key":"2766_CR73","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","volume":"13","author":"A Bianchi","year":"2023","unstructured":"Bianchi A, De Castro Silva I, Deshpande NU, Singh S, Mehra S, Garrido VT, et al. Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer. Cancer Discov. 2023;13:1428\u201353.","journal-title":"Cancer Discov"},{"key":"2766_CR74","doi-asserted-by":"crossref","unstructured":"Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, et al. Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. Oncologist. 2025;30:oyaf362.","DOI":"10.1093\/oncolo\/oyaf362"},{"key":"2766_CR75","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41467-025-56441-5","volume":"16","author":"L van Hijfte","year":"2025","unstructured":"van Hijfte L, Geurts M, de Heer I, Ghisai SA, Balcioglu HE, Hoogstrate Y, et al. Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma. Nat Commun. 2025;16:1156.","journal-title":"Nat Commun"},{"key":"2766_CR76","doi-asserted-by":"publisher","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","volume":"385","author":"MJ Wu","year":"2024","unstructured":"Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024;385:eadl6173.","journal-title":"Science"},{"key":"2766_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s40425-019-0780-0","volume":"7","author":"JA Trujillo","year":"2019","unstructured":"Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, et al. Secondary resistance to immunotherapy associated with \u03b2-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019;7:295.","journal-title":"J Immunother Cancer"},{"key":"2766_CR78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41698-025-01045-x","volume":"9","author":"T Vougiouklakis","year":"2025","unstructured":"Vougiouklakis T, Vanderbilt C, Rana S, Mohanty A, Pareja F, Brogi E, et al. Genomic characterization of tumor mutational burden-high breast carcinomas. NPJ Precis Oncol. 2025;9:277.","journal-title":"NPJ Precis Oncol"},{"key":"2766_CR79","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2023;14:1516.","journal-title":"Nat Commun"},{"key":"2766_CR80","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12885-021-08114-x","volume":"21","author":"Z Lin","year":"2021","unstructured":"Lin Z, Huang L, Li SL, Gu J, Cui X, Zhou Y. PTEN loss correlates with T cell exclusion across human cancers. BMC Cancer. 2021;21:429.","journal-title":"BMC Cancer"},{"key":"2766_CR81","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17:399\u2013410.","journal-title":"J Thorac Oncol"},{"key":"2766_CR82","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822\u201335.","journal-title":"Cancer Discov"},{"key":"2766_CR83","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","volume":"31","author":"D Marinelli","year":"2020","unstructured":"Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D\u2019Ambrosio L, et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020;31:1746\u201354.","journal-title":"Ann Oncol"},{"key":"2766_CR84","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/nm.4407","volume":"23","author":"R Romero","year":"2017","unstructured":"Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23:1362\u20138.","journal-title":"Nat Med"},{"key":"2766_CR85","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s13402-025-01157-3","volume":"49","author":"M Padelli","year":"2026","unstructured":"Padelli M, Desterke C, Devocelle A, Uzan G, Lemoine A, Giron-Michel J. The epigenetic regulator SETDB1 as a key component of cancer stem cells and drug resistance in primary liver cancer. Cell Oncol (Dordr). 2026;49:18.","journal-title":"Cell Oncol (Dordr)"},{"key":"2766_CR86","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595:309\u201314.","journal-title":"Nature"},{"key":"2766_CR87","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molcel.2022.09.007","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y, Goldberg EM, Chen X, Xu X, McGuire JT, Leuzzi G, et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell. 2022;82:3901-3918.e3907.","journal-title":"Mol Cell"},{"key":"2766_CR88","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1158\/0008-5472.CAN-22-3114","volume":"83","author":"C Chen","year":"2023","unstructured":"Chen C, Shin JH, Fang Z, Brennan K, Horowitz NB, Pfaff KL, et al. Targeting KDM2A enhances T-cell infiltration in NSD1-deficient head and neck squamous cell carcinoma. Cancer Res. 2023;83:2645\u201355.","journal-title":"Cancer Res"},{"key":"2766_CR89","doi-asserted-by":"crossref","unstructured":"Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13:eaaz6804.","DOI":"10.1126\/scitranslmed.aaz6804"},{"key":"2766_CR90","doi-asserted-by":"publisher","first-page":"e70393","DOI":"10.1002\/cam4.70393","volume":"13","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al. Molecular characterization and clinical relevance of MGMT-silenced pancreatic cancer. Cancer Med. 2024;13:e70393.","journal-title":"Cancer Med"},{"key":"2766_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72204-2","author":"J Choo","year":"2026","unstructured":"Choo J, Zhao JJ, Lau MC, Raimondi A, Yim WW, Ranganathan S, et al. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-72204-2.","journal-title":"Nat Commun"},{"key":"2766_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","volume":"44","author":"Y Liu","year":"2026","unstructured":"Liu Y, Dai Y, Wang L. Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications. Cancer Cell. 2026;44:24\u201349.","journal-title":"Cancer Cell"},{"key":"2766_CR93","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Sali\u00e9 H, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 2022;40:639-655.e613.","journal-title":"Cancer Cell"},{"key":"2766_CR94","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/s41467-025-58452-8","volume":"16","author":"KKH Yu","year":"2025","unstructured":"Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, et al. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nat Commun. 2025;16:3957.","journal-title":"Nat Commun"},{"key":"2766_CR95","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jhep.2025.02.045","volume":"83","author":"S Zhou","year":"2025","unstructured":"Zhou S, Zhang L, You Y, Yu K, Tie X, Gao Y, et al. eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma. J Hepatol. 2025;83:712\u201328.","journal-title":"J Hepatol"},{"key":"2766_CR96","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-024-01596-9","volume":"17","author":"X Liu","year":"2024","unstructured":"Liu X, Peng T, Xu M, Lin S, Hu B, Chu T, et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J Hematol Oncol. 2024;17:72.","journal-title":"J Hematol Oncol"},{"key":"2766_CR97","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aaf2403","volume":"353","author":"PL St\u00e5hl","year":"2016","unstructured":"St\u00e5hl PL, Salm\u00e9n F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353:78\u201382.","journal-title":"Science"},{"key":"2766_CR98","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41588-025-02193-3","volume":"57","author":"MF Oliveira","year":"2025","unstructured":"Oliveira MF, Romero JP, Chung M, Williams SR, Gottscho AD, Gupta A, et al. High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer. Nat Genet. 2025;57:1512\u201323.","journal-title":"Nat Genet"},{"key":"2766_CR99","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaw1219","volume":"363","author":"SG Rodriques","year":"2019","unstructured":"Rodriques SG, Stickels RR, Goeva A, Martin CA, Murray E, Vanderburg CR, et al. Slide-seq: a scalable technology for measuring genome-wide expression at high spatial resolution. Science. 2019;363:1463\u20137.","journal-title":"Science"},{"key":"2766_CR100","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1038\/s41467-025-59005-9","volume":"16","author":"Y Dong","year":"2025","unstructured":"Dong Y, Saglietti C, Bayard Q, Espin Perez A, Carpentier S, Buszta D, et al. Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneity. Nat Commun. 2025;16:4400.","journal-title":"Nat Commun"},{"key":"2766_CR101","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13073-024-01422-4","volume":"16","author":"R Li","year":"2024","unstructured":"Li R, Li N, Yang Q, Tong X, Wang W, Li C, et al. Spatial transcriptome profiling identifies DTX3L and BST2 as key biomarkers in esophageal squamous cell carcinoma tumorigenesis. Genome Med. 2024;16:148.","journal-title":"Genome Med"},{"key":"2766_CR102","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1912459116","volume":"116","author":"C Xia","year":"2019","unstructured":"Xia C, Fan J, Emanuel G, Hao J, Zhuang X. Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression. Proc Natl Acad Sci U S A. 2019;116:19490\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2766_CR103","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","volume":"568","author":"CL Eng","year":"2019","unstructured":"Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568:235\u20139.","journal-title":"Nature"},{"key":"2766_CR104","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s41592-025-02617-2","volume":"22","author":"S Marco Salas","year":"2025","unstructured":"Marco Salas S, Kuemmerle LB, Mattsson-Langseth C, Tismeyer S, Avenel C, Hu T, et al. Optimizing Xenium In Situ data utility by quality assessment and best-practice analysis workflows. Nat Methods. 2025;22:813\u201323.","journal-title":"Nat Methods"},{"key":"2766_CR105","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13578-024-01199-4","volume":"14","author":"MJ Abraham","year":"2024","unstructured":"Abraham MJ, Goncalves C, McCallum P, Gupta V, Preston SEJ, Huang F, et al. Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments. Cell Biosci. 2024;14:19.","journal-title":"Cell Biosci"},{"key":"2766_CR106","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","volume":"40","author":"S He","year":"2022","unstructured":"He S, Bhatt R, Brown C, Brown EA, Buhr DL, Chantranuvatana K, et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat Biotechnol. 2022;40:1794\u2013806.","journal-title":"Nat Biotechnol"},{"key":"2766_CR107","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1038\/s41598-024-55387-w","volume":"14","author":"V Navikas","year":"2024","unstructured":"Navikas V, Kowal J, Rodriguez D, Rivest F, Brajkovic S, Cassano M, et al. Semi-automated approaches for interrogating spatial heterogeneity of tissue samples. Sci Rep. 2024;14:5025.","journal-title":"Sci Rep"},{"key":"2766_CR108","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/labinvest.2014.156","volume":"95","author":"M Aichler","year":"2015","unstructured":"Aichler M, Walch A. MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95:422\u201331.","journal-title":"Lab Invest"},{"key":"2766_CR109","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41:404\u201320.","journal-title":"Cancer Cell"},{"key":"2766_CR110","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41587-020-0739-1","volume":"39","author":"RR Stickels","year":"2021","unstructured":"Stickels RR, Murray E, Kumar P, Li J, Marshall JL, Di Bella DJ, et al. Highly sensitive spatial transcriptomics at near-cellular resolution with Slide-seqV2. Nat Biotechnol. 2021;39:313\u20139.","journal-title":"Nat Biotechnol"},{"key":"2766_CR111","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1038\/s41467-025-58511-0","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Wang Z, Liao Q, Yuan P, Mei J, Zhang Y, et al. Spatially resolved atlas of breast cancer uncovers intercellular machinery of venular niche governing lymphocyte extravasation. Nat Commun. 2025;16:3348.","journal-title":"Nat Commun"},{"key":"2766_CR112","doi-asserted-by":"publisher","first-page":"e2203040","DOI":"10.1002\/advs.202203040","volume":"9","author":"Z Ou","year":"2022","unstructured":"Ou Z, Lin S, Qiu J, Ding W, Ren P, Chen D, et al. Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma. Adv Sci (Weinh). 2022;9:e2203040.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR113","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ard.2025.04.025","volume":"84","author":"Z Li","year":"2025","unstructured":"Li Z, Rius Rigau A, Xie W, Huang L, Ye W, Li YN, et al. Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis. Ann Rheum Dis. 2025;84:1231\u201345.","journal-title":"Ann Rheum Dis"},{"key":"2766_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Chen X, Feng L, Yang Z, Xiao L, Xiang B, et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 2025;11:1.","journal-title":"Cell Discov"},{"key":"2766_CR115","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/s41592-024-02325-3","volume":"21","author":"Y You","year":"2024","unstructured":"You Y, Fu Y, Li L, Zhang Z, Jia S, Lu S, et al. Systematic comparison of sequencing-based spatial transcriptomic methods. Nat Methods. 2024;21:1743\u201354.","journal-title":"Nat Methods"},{"key":"2766_CR116","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1038\/s41467-025-64292-3","volume":"16","author":"P Ren","year":"2025","unstructured":"Ren P, Zhang R, Wang Y, Zhang P, Luo C, Wang S, et al. Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms across human tumors. Nat Commun. 2025;16:9232.","journal-title":"Nat Commun"},{"key":"2766_CR117","doi-asserted-by":"publisher","first-page":"8499","DOI":"10.1038\/s41467-025-63414-1","volume":"16","author":"N Ozirmak Lermi","year":"2025","unstructured":"Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, et al. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nat Commun. 2025;16:8499.","journal-title":"Nat Commun"},{"key":"2766_CR118","doi-asserted-by":"crossref","unstructured":"Plummer JT, Dezem FS, Cook DP, Park J, Zhang L, Liu Y, et al. Standardized metrics for assessment and reproducibility of imaging-based spatial transcriptomics datasets. Nat Biotechnol. 2026;44:1213\u201325.","DOI":"10.1038\/s41587-025-02811-9"},{"key":"2766_CR119","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-025-08584-0","volume":"638","author":"T Guo","year":"2025","unstructured":"Guo T, Steen JA, Mann M. Mass-spectrometry-based proteomics: from single cells to clinical applications. Nature. 2025;638:901\u201311.","journal-title":"Nature"},{"key":"2766_CR120","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41580-018-0094-y","volume":"20","author":"E Lundberg","year":"2019","unstructured":"Lundberg E, Borner GHH. Spatial proteomics: a powerful discovery tool for cell biology. Nat Rev Mol Cell Biol. 2019;20:285\u2013302.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2766_CR121","doi-asserted-by":"publisher","first-page":"vbad046","DOI":"10.1093\/bioadv\/vbad046","volume":"3","author":"V Milosevic","year":"2023","unstructured":"Milosevic V. Different approaches to imaging mass cytometry data analysis. Bioinformatics Adv. 2023;3:vbad046.","journal-title":"Bioinformatics Adv"},{"key":"2766_CR122","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41581-025-01007-3","volume":"22","author":"K Sharma","year":"2026","unstructured":"Sharma K, Hansen J, Susztak K, Eberlin L, Anderton CR, Alexandrov T, et al. Spatial metabolomics and multiomics integration for breakthroughs in precision medicine for kidney disease. Nat Rev Nephrol. 2026;22:152\u201364.","journal-title":"Nat Rev Nephrol"},{"key":"2766_CR123","doi-asserted-by":"publisher","first-page":"1589943","DOI":"10.3389\/fimmu.2025.1589943","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Zhang Y, Li X, Zhang Y, Zeng Y. Driving innovations in cancer research through spatial metabolomics: a bibliometric review of trends and hotspot. Front Immunol. 2025;16:1589943.","journal-title":"Front Immunol"},{"key":"2766_CR124","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1021\/acs.accounts.3c00382","volume":"56","author":"NM Morato","year":"2023","unstructured":"Morato NM, Cooks RG. Desorption electrospray ionization mass spectrometry: 20 years. Acc Chem Res. 2023;56:2526\u201336.","journal-title":"Acc Chem Res"},{"key":"2766_CR125","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s43586-024-00311-9","volume":"4","author":"NP Lockyer","year":"2024","unstructured":"Lockyer NP, Aoyagi S, Fletcher JS, Gilmore IS, van der Heide PAW, Moore KL, et al. Secondary ion mass spectrometry. Nat Rev Methods Primers. 2024;4:32.","journal-title":"Nat Rev Methods Primers"},{"key":"2766_CR126","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41587-023-01676-0","volume":"41","author":"Y Liu","year":"2023","unstructured":"Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, et al. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nat Biotechnol. 2023;41:1405\u20139.","journal-title":"Nat Biotechnol"},{"key":"2766_CR127","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41467-022-28445-y","volume":"13","author":"S Vickovic","year":"2022","unstructured":"Vickovic S, L\u00f6tstedt B, Klughammer J, Mages S, Segerstolpe \u00c5, Rozenblatt-Rosen O, et al. SM-Omics is an automated platform for high-throughput spatial multi-omics. Nat Commun. 2022;13:795.","journal-title":"Nat Commun"},{"key":"2766_CR128","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2020.10.026","volume":"183","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang M, Deng Y, Su G, Enninful A, Guo CC, et al. High-spatial-resolution multi-omics sequencing via deterministic barcoding in tissue. Cell. 2020;183:1665-1681.e1618.","journal-title":"Cell"},{"key":"2766_CR129","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41587-023-01937-y","volume":"42","author":"M Vicari","year":"2024","unstructured":"Vicari M, Mirzazadeh R, Nilsson A, Shariatgorji R, Bj\u00e4rterot P, Larsson L, et al. Spatial multimodal analysis of transcriptomes and metabolomes in tissues. Nat Biotechnol. 2024;42:1046\u201350.","journal-title":"Nat Biotechnol"},{"key":"2766_CR130","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1038\/s41467-025-63915-z","volume":"16","author":"R Tian","year":"2025","unstructured":"Tian R, Xue Z, Chen Y, Qi Y, Zhang J, Yuan J, et al. Integrating cross-sample and cross-modal data for spatial transcriptomics and metabolomics with SpatialMETA. Nat Commun. 2025;16:8855.","journal-title":"Nat Commun"},{"key":"2766_CR131","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41551-024-01205-7","volume":"8","author":"X Wu","year":"2024","unstructured":"Wu X, Xu W, Deng L, Li Y, Wang Z, Sun L, et al. Spatial multi-omics at subcellular resolution via high-throughput in situ pairwise sequencing. Nat Biomed Eng. 2024;8:872\u201389.","journal-title":"Nat Biomed Eng"},{"key":"2766_CR132","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41592-024-02576-0","volume":"22","author":"P Guo","year":"2025","unstructured":"Guo P, Mao L, Chen Y, Lee CN, Cardilla A, Li M, et al. Multiplexed spatial mapping of chromatin features, transcriptome and proteins in tissues. Nat Methods. 2025;22:520\u20139.","journal-title":"Nat Methods"},{"key":"2766_CR133","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1038\/s41467-022-32111-8","volume":"13","author":"X Shao","year":"2022","unstructured":"Shao X, Li C, Yang H, Lu X, Liao J, Qian J, et al. Knowledge-graph-based cell-cell communication inference for spatially resolved transcriptomic data with SpaTalk. Nat Commun. 2022;13:4429.","journal-title":"Nat Commun"},{"key":"2766_CR134","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-024-51329-2","volume":"15","author":"W Yang","year":"2024","unstructured":"Yang W, Wang P, Xu S, Wang T, Luo M, Cai Y, et al. Deciphering cell-cell communication at single-cell resolution for spatial transcriptomics with subgraph-based graph attention network. Nat Commun. 2024;15:7101.","journal-title":"Nat Commun"},{"key":"2766_CR135","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cels.2024.05.001","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang J, Gao X, Zhang QC. Tissue module discovery in single-cell-resolution spatial transcriptomics data via cell-cell interaction-aware cell embedding. Cell Syst. 2024;15:578-592.e577.","journal-title":"Cell Syst"},{"key":"2766_CR136","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1038\/s41467-024-54973-w","volume":"15","author":"A Agrawal","year":"2024","unstructured":"Agrawal A, Thomann S, Basu S, Gr\u00fcn D. Nico identifies extrinsic drivers of cell state modulation by niche covariation analysis. Nat Commun. 2024;15:10628.","journal-title":"Nat Commun"},{"key":"2766_CR137","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1016\/j.cell.2024.10.011","volume":"187","author":"X Qiu","year":"2024","unstructured":"Qiu X, Zhu DY, Lu Y, Yao J, Jing Z, Min KH, et al. Spatiotemporal modeling of molecular holograms. Cell. 2024;187:7351-7373.e7361.","journal-title":"Cell"},{"key":"2766_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giae078","author":"X Liu","year":"2024","unstructured":"Liu X, Qu C, Liu C, Zhu N, Huang H, Teng F, et al. StereoSiTE: a framework to spatially and quantitatively profile the cellular neighborhood organized iTME. Gigascience. 2024. https:\/\/doi.org\/10.1093\/gigascience\/giae078.","journal-title":"Gigascience"},{"key":"2766_CR139","doi-asserted-by":"publisher","first-page":"911873","DOI":"10.3389\/fimmu.2022.911873","volume":"13","author":"M Tran","year":"2022","unstructured":"Tran M, Yoon S, Teoh M, Andersen S, Lam PY, Purdue BW, et al. A robust experimental and computational analysis framework at multiple resolutions, modalities and coverages. Front Immunol. 2022;13:911873.","journal-title":"Front Immunol"},{"key":"2766_CR140","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13059-022-02663-5","volume":"23","author":"J Tanevski","year":"2022","unstructured":"Tanevski J, Flores ROR, Gabor A, Schapiro D, Saez-Rodriguez J. Explainable multiview framework for dissecting spatial relationships from highly multiplexed data. Genome Biol. 2022;23:97.","journal-title":"Genome Biol"},{"key":"2766_CR141","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/bioinformatics\/btaa769","volume":"37","author":"D Li","year":"2021","unstructured":"Li D, Ding J, Bar-Joseph Z. Identifying signaling genes in spatial single-cell expression data. Bioinformatics. 2021;37:968\u201375.","journal-title":"Bioinformatics"},{"key":"2766_CR142","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41588-025-02120-6","volume":"57","author":"S Birk","year":"2025","unstructured":"Birk S, Bonafonte-Pard\u00e0s I, Feriz AM, Boxall A, Agirre E, Memi F, et al. Quantitative characterization of cell niches in spatially resolved omics data. Nat Genet. 2025;57:897\u2013909.","journal-title":"Nat Genet"},{"key":"2766_CR143","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41592-024-02408-1","volume":"21","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wang Y, Chang WY, Malewska A, Napolitano F, Gahan JC, et al. Mapping cellular interactions from spatially resolved transcriptomics data. Nat Methods. 2024;21:1830\u201342.","journal-title":"Nat Methods"},{"key":"2766_CR144","doi-asserted-by":"publisher","first-page":"i484","DOI":"10.1093\/bioinformatics\/btad269","volume":"39","author":"M Bafna","year":"2023","unstructured":"Bafna M, Li H, Zhang X. CLARIFY: cell-cell interaction and gene regulatory network refinement from spatially resolved transcriptomics. Bioinformatics. 2023;39:i484\u201393.","journal-title":"Bioinformatics"},{"key":"2766_CR145","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13059-023-03159-6","volume":"25","author":"K Mason","year":"2024","unstructured":"Mason K, Sathe A, Hess PR, Rong J, Wu CY, Furth E, et al. Niche-DE: niche-differential gene expression analysis in spatial transcriptomics data identifies context-dependent cell-cell interactions. Genome Biol. 2024;25:14.","journal-title":"Genome Biol"},{"key":"2766_CR146","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13059-022-02692-0","volume":"23","author":"R Li","year":"2022","unstructured":"Li R, Yang X. De novo reconstruction of cell interaction landscapes from single-cell spatial transcriptome data with DeepLinc. Genome Biol. 2022;23:124.","journal-title":"Genome Biol"},{"key":"2766_CR147","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13059-020-02214-w","volume":"21","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Bar-Joseph Z. GCNG: graph convolutional networks for inferring gene interaction from spatial transcriptomics data. Genome Biol. 2020;21:300.","journal-title":"Genome Biol"},{"key":"2766_CR148","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1038\/s41467-023-39608-w","volume":"14","author":"Z Li","year":"2023","unstructured":"Li Z, Wang T, Liu P, Huang Y. SpatialDM for rapid identification of spatially co-expressed ligand-receptor and revealing cell-cell communication patterns. Nat Commun. 2023;14:3995.","journal-title":"Nat Commun"},{"key":"2766_CR149","doi-asserted-by":"crossref","unstructured":"Tang Z, Zhang T, Yang B, Su J, Song Q. spaCI: deciphering spatial cellular communications through adaptive graph model. Brief Bioinform 2023;24.","DOI":"10.1093\/bib\/bbac563"},{"key":"2766_CR150","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1093\/bioinformatics\/btac599","volume":"38","author":"T Tsuchiya","year":"2022","unstructured":"Tsuchiya T, Hori H, Ozaki H. CCPLS reveals cell-type-specific spatial dependence of transcriptomes in single cells. Bioinformatics. 2022;38:4868\u201377.","journal-title":"Bioinformatics"},{"key":"2766_CR151","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13059-021-02286-2","volume":"22","author":"R Dries","year":"2021","unstructured":"Dries R, Zhu Q, Dong R, Eng CL, Li H, Liu K, et al. Giotto: a toolbox for integrative analysis and visualization of spatial expression data. Genome Biol. 2021;22:78.","journal-title":"Genome Biol"},{"key":"2766_CR152","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/s41467-020-15968-5","volume":"11","author":"Z Cang","year":"2020","unstructured":"Cang Z, Nie Q. Inferring spatial and signaling relationships between cells from single cell transcriptomic data. Nat Commun. 2020;11:2084.","journal-title":"Nat Commun"},{"key":"2766_CR153","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41587-022-01467-z","volume":"41","author":"DS Fischer","year":"2023","unstructured":"Fischer DS, Schaar AC, Theis FJ. Modeling intercellular communication in tissues using spatial graphs of cells. Nat Biotechnol. 2023;41:332\u20136.","journal-title":"Nat Biotechnol"},{"key":"2766_CR154","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41592-022-01728-4","volume":"20","author":"Z Cang","year":"2023","unstructured":"Cang Z, Zhao Y, Almet AA, Stabell A, Ramos R, Plikus MV, et al. Screening cell-cell communication in spatial transcriptomics via collective optimal transport. Nat Methods. 2023;20:218\u201328.","journal-title":"Nat Methods"},{"key":"2766_CR155","doi-asserted-by":"crossref","unstructured":"Li H, Ma T, Hao M, Guo W, Gu J, Zhang X, et al. Decoding functional cell-cell communication events by multi-view graph learning on spatial transcriptomics. Brief Bioinform. 2023;24:bbad359.","DOI":"10.1093\/bib\/bbad359"},{"key":"2766_CR156","doi-asserted-by":"crossref","unstructured":"Huang S, Ran Q, Tang J, Wang X, Xi J, Ma S, et al. SpaNiche: spatial niche analysis to explore colocalization patterns and cellular interactions in spatial transcriptomics data. Genome Biol. 2026;27:182.","DOI":"10.1186\/s13059-026-04069-z"},{"key":"2766_CR157","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s43018-024-00904-z","volume":"6","author":"M Ritter","year":"2025","unstructured":"Ritter M, Blume C, Tang Y, Patel A, Patel B, Berghaus N, et al. Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics. Nat Cancer. 2025;6:292\u2013306.","journal-title":"Nat Cancer"},{"key":"2766_CR158","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1158\/2159-8290.CD-23-1499","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Li M, Hwang TH. The 3D revolution in cancer discovery. Cancer Discov. 2024;14:625\u20139.","journal-title":"Cancer Discov"},{"key":"2766_CR159","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41586-024-08087-4","volume":"634","author":"CK Mo","year":"2024","unstructured":"Mo CK, Liu J, Chen S, Storrs E, Targino da Costa ALN, Houston A, et al. Tumour evolution and microenvironment interactions in 2D and 3D space. Nature. 2024;634:1178\u201386.","journal-title":"Nature"},{"key":"2766_CR160","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2022.12.028","volume":"186","author":"JR Lin","year":"2023","unstructured":"Lin JR, Wang S, Coy S, Chen YA, Yapp C, Tyler M, et al. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell. 2023;186:363-381.e319.","journal-title":"Cell"},{"key":"2766_CR161","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-024-07359-3","volume":"629","author":"AM Braxton","year":"2024","unstructured":"Braxton AM, Kiemen AL, Grahn MP, Forjaz A, Parksong J, Mahesh Babu J, et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. Nature. 2024;629:679\u201387.","journal-title":"Nature"},{"key":"2766_CR162","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41592-025-02824-x","volume":"22","author":"C Yapp","year":"2025","unstructured":"Yapp C, Nirmal AJ, Zhou F, Wong AYH, Tefft JB, Lu YD, et al. Highly multiplexed 3D profiling of cell states and immune niches in human tumors. Nat Methods. 2025;22:2180\u201393.","journal-title":"Nat Methods"},{"key":"2766_CR163","doi-asserted-by":"crossref","unstructured":"Glaser AK, Reder NP, Chen Y, McCarty EF, Yin C, Wei L, et al. Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens. Nat Biomed Eng. 2017;1:0084.","DOI":"10.1038\/s41551-017-0084"},{"key":"2766_CR164","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41467-025-59820-0","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Shin SJ, Kim G, Cho H, Ryu D, Ahn D, et al. Revealing 3D microanatomical structures of unlabeled thick cancer tissues using holotomography and virtual H&E staining. Nat Commun. 2025;16:4781.","journal-title":"Nat Commun"},{"key":"2766_CR165","doi-asserted-by":"crossref","unstructured":"Tang C, Zhou Y, Xiao X, Dong L, Yu L, Li Q, et al. 3D reconstruction of spatial transcriptomics with spatial pattern enhanced graph convolutional neural network. Brief Bioinform. 2026;27:bbag060.","DOI":"10.1093\/bib\/bbag060"},{"key":"2766_CR166","doi-asserted-by":"publisher","first-page":"D1281","DOI":"10.1093\/nar\/gkaf998","volume":"54","author":"H Zhao","year":"2026","unstructured":"Zhao H, Yin X, Wang S, Geng Z, Yu W, Yu H, et al. So3D: a comprehensive three-dimensional spatial omics resource for decoding tissue architecture in physiology and disease. Nucleic Acids Res. 2026;54:D1281-d1290.","journal-title":"Nucleic Acids Res"},{"key":"2766_CR167","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41592-022-01468-5","volume":"19","author":"AK Glaser","year":"2022","unstructured":"Glaser AK, Bishop KW, Barner LA, Susaki EA, Kubota SI, Gao G, et al. A hybrid open-top light-sheet microscope for versatile multi-scale imaging of cleared tissues. Nat Methods. 2022;19:613\u20139.","journal-title":"Nat Methods"},{"key":"2766_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.05.031","author":"Y Li","year":"2026","unstructured":"Li Y, Li Z, Quinton R, Ji Y, Zhang X, Xiang J, et al. Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology. Cell. 2026. https:\/\/doi.org\/10.1016\/j.cell.2026.05.031.","journal-title":"Cell"},{"key":"2766_CR169","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.xgen.2025.101105","volume":"6","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Ming W, Yu B, Wang L, Lu K, Xu L, et al. Robust integration and annotation of single-cell and spatial omics data using interpretable gene programs. Cell Genom. 2026;6:101105.","journal-title":"Cell Genom"},{"key":"2766_CR170","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ccell.2024.08.011","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, de Souza N, Bodenmiller B. Classifying cancer-associated fibroblasts-the good, the bad, and the target. Cancer Cell. 2024;42:1480\u20135.","journal-title":"Cancer Cell"},{"key":"2766_CR171","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22:159.","journal-title":"Mol Cancer"},{"key":"2766_CR172","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1111\/cas.14664","volume":"111","author":"K Miyazaki","year":"2020","unstructured":"Miyazaki K, Togo S, Okamoto R, Idiris A, Kumagai H, Miyagi Y. Collective cancer cell invasion in contact with fibroblasts through integrin-\u03b15\u03b21\/fibronectin interaction in collagen matrix. Cancer Sci. 2020;111:4381\u201392.","journal-title":"Cancer Sci"},{"key":"2766_CR173","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13046-025-03327-5","volume":"44","author":"I Masi","year":"2025","unstructured":"Masi I, Ottavi F, Caprara V, Rio DD, Kunkl M, Spadaro F, et al. The extracellular matrix protein type I collagen and fibronectin are regulated by \u03b2-arrestin-1\/endothelin axis in human ovarian fibroblasts. J Exp Clin Cancer Res. 2025;44:64.","journal-title":"J Exp Clin Cancer Res"},{"key":"2766_CR174","doi-asserted-by":"publisher","first-page":"1363004","DOI":"10.3389\/fcell.2024.1363004","volume":"12","author":"G Guerrero-Barber\u00e0","year":"2024","unstructured":"Guerrero-Barber\u00e0 G, Burday N, Costell M. Shaping oncogenic microenvironments: contribution of fibronectin. Front Cell Dev Biol. 2024;12:1363004.","journal-title":"Front Cell Dev Biol"},{"key":"2766_CR175","doi-asserted-by":"publisher","first-page":"e14661","DOI":"10.1002\/advs.202514661","volume":"12","author":"Y Li","year":"2025","unstructured":"Li Y, Huan C, Sun H, Zhang W, Guo Z, Li C, et al. Spatial transcriptomics and snRNA-seq expose CAF niches orchestrating dual stromal-immune barriers in hepatocellular carcinoma. Adv Sci (Weinh). 2025;12:e14661.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR176","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout JA, Sirven P, Leader AM, Maskey S, Hector E, Puisieux I, et al. Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 2022;12:2606\u201325.","journal-title":"Cancer Discov"},{"key":"2766_CR177","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599:673\u20138.","journal-title":"Nature"},{"key":"2766_CR178","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","volume":"14","author":"KSS Enfield","year":"2024","unstructured":"Enfield KSS, Colliver E, Lee C, Magness A, Moore DA, Sivakumar M, et al. Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer. Cancer Discov. 2024;14:1018\u201347.","journal-title":"Cancer Discov"},{"key":"2766_CR179","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122:899\u2013910.","journal-title":"J Clin Invest"},{"key":"2766_CR180","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2017.11.026","volume":"415","author":"Z Yang","year":"2018","unstructured":"Yang Z, Jin P, Xu S, Zhang T, Yang X, Li X, et al. Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer. Cancer Lett. 2018;415:20\u20139.","journal-title":"Cancer Lett"},{"key":"2766_CR181","doi-asserted-by":"publisher","first-page":"339","DOI":"10.7150\/ijbs.17680","volume":"13","author":"Z Wang","year":"2017","unstructured":"Wang Z, Tan Y, Yu W, Zheng S, Zhang S, Sun L, et al. Small role with big impact: miRNAs as communicators in the cross-talk between cancer-associated fibroblasts and cancer cells. Int J Biol Sci. 2017;13:339\u201348.","journal-title":"Int J Biol Sci"},{"key":"2766_CR182","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/gutjnl-2022-329371","volume":"72","author":"E Karamitopoulou","year":"2023","unstructured":"Karamitopoulou E, Wenning AS, Acharjee A, Zlobec I, Aeschbacher P, Perren A, et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut. 2023;72:1523\u201333.","journal-title":"Gut"},{"key":"2766_CR183","doi-asserted-by":"publisher","first-page":"e20547","DOI":"10.1002\/advs.202520547","volume":"13","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Yao S, Zhao Y, Zhu S, Fang W, Yu R, et al. STING agonist-modified tumor targeting photosensitizer remodels cancer-associated fibroblasts to potentiate photoimmunotherapy in pancreatic cancer. Adv Sci (Weinh). 2026;13:e20547.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR184","doi-asserted-by":"publisher","first-page":"101934","DOI":"10.1016\/j.xcrm.2025.101934","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud F, Gu\u00e9gan JP, Rey C, Lara O, Odin O, Del Castillo M, et al. Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures. Cell Rep Med. 2025;6:101934.","journal-title":"Cell Rep Med"},{"key":"2766_CR185","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-025-03432-5","volume":"44","author":"Z Lin","year":"2025","unstructured":"Lin Z, Zhou Y, Liu Z, Nie W, Cao H, Li S, et al. Deciphering the tumor immune microenvironment: single-cell and spatial transcriptomic insights into cervical cancer fibroblasts. J Exp Clin Cancer Res. 2025;44:194.","journal-title":"J Exp Clin Cancer Res"},{"key":"2766_CR186","doi-asserted-by":"crossref","unstructured":"Wang H, Liang Y, Liu Z, Zhang R, Chao J, Wang M, Liu M, Qiao L, Xuan Z, Zhao H, Lu L. POSTN(+) cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2024;12:e008721.","DOI":"10.1136\/jitc-2023-008721"},{"key":"2766_CR187","doi-asserted-by":"publisher","first-page":"102682","DOI":"10.1016\/j.tranon.2026.102682","volume":"65","author":"Y Wang","year":"2026","unstructured":"Wang Y, Yue B, Ni H, Chen J, Shi R, Wang Z, et al. POSTN\u207a cancer-associated fibroblast-CCL3\u207a macrophage crosstalk defines the immune-excluded tumor microenvironment in clear cell renal cell carcinoma. Transl Oncol. 2026;65:102682.","journal-title":"Transl Oncol"},{"key":"2766_CR188","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.14336\/AD.2023.0503","volume":"14","author":"T You","year":"2023","unstructured":"You T, Tang H, Wu W, Gao J, Li X, Li N, et al. POSTN secretion by extracellular matrix cancer-associated fibroblasts (eCAFs) correlates with poor ICB response via macrophage chemotaxis activation of Akt signaling pathway in gastric cancer. Aging Dis. 2023;14:2177\u201392.","journal-title":"Aging Dis"},{"key":"2766_CR189","doi-asserted-by":"publisher","first-page":"e10847","DOI":"10.1002\/advs.202510847","volume":"13","author":"B Qing","year":"2026","unstructured":"Qing B, Li X, He X, Wang J, Yang Y, Jiang M, et al. Characterizing stage-specific cellular dynamics and microenvironmental remodeling in lung adenocarcinoma by single-cell RNA sequencing. Adv Sci (Weinh). 2026;13:e10847.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR190","first-page":"0950","volume":"8","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Zhang K, Wu W, Zhou J, Zhang M, Chen J, et al. POSTN(+) CAF-Derived Migrasomes Drive Hepatocellular Carcinoma Progression and Confer Resistance to Immunotherapy. Research (Wash D C). 2025;8:0950.","journal-title":"Research (Wash D C)"},{"key":"2766_CR191","doi-asserted-by":"publisher","first-page":"e71546","DOI":"10.1096\/fj.202504456RR","volume":"40","author":"H Chen","year":"2026","unstructured":"Chen H, Peng Y, Ji Z, Dong J. SPP1(+) macrophage-POSTN(+) fibroblast-endothelial triad dictates immunotherapy response in bladder cancer. FASEB J. 2026;40:e71546.","journal-title":"FASEB J"},{"key":"2766_CR192","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. 2022;13:1742.","journal-title":"Nat Commun"},{"key":"2766_CR193","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.7150\/thno.99046","volume":"14","author":"F Long","year":"2024","unstructured":"Long F, Zhong W, Zhao F, Xu Y, Hu X, Jia G, et al. DAB2 (+) macrophages support FAP (+) fibroblasts in shaping tumor barrier and inducing poor clinical outcomes in liver cancer. Theranostics. 2024;14:4822\u201343.","journal-title":"Theranostics"},{"key":"2766_CR194","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78:770\u201382.","journal-title":"J Hepatol"},{"key":"2766_CR195","doi-asserted-by":"crossref","unstructured":"Chang M, Feng M, Lei Y, Wang Y, Bai L, Wang Y. Integrated single-cell and spatial transcriptomic analysis reveals mCAF-SPP1\u207a macrophage-T cell crosstalk shaping immunosuppressive niches in colorectal cancer liver metastasis. J Transl Med. 2026;24:529.","DOI":"10.1186\/s12967-026-07978-6"},{"key":"2766_CR196","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","volume":"5","author":"KM Tharp","year":"2024","unstructured":"Tharp KM, Kersten K, Maller O, Timblin GA, Stashko C, Canale FP, et al. Tumor-associated macrophages restrict CD8(+) T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat Cancer. 2024;5:1045\u201362.","journal-title":"Nat Cancer"},{"key":"2766_CR197","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41556-025-01840-5","volume":"28","author":"L Wang","year":"2026","unstructured":"Wang L, Chu H, Chen D, Wei Y, Jia J, Li L, et al. SLC2A1(+) tumour-associated macrophages spatially control CD8(+) T cell function and drive resistance to immunotherapy in non-small-cell lung cancer. Nat Cell Biol. 2026;28:338\u201348.","journal-title":"Nat Cell Biol"},{"key":"2766_CR198","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341.","journal-title":"Cell"},{"key":"2766_CR199","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"A De Leo","year":"2024","unstructured":"De Leo A, Ugolini A, Yu X, Scirocchi F, Scocozza D, Peixoto B, et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. 2024;57:1105-1123.e1108.","journal-title":"Immunity"},{"key":"2766_CR200","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"SM Morrissey","year":"2021","unstructured":"Morrissey SM, Zhang F, Ding C, Montoya-Durango DE, Hu X, Yang C, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33:2040-2058.e2010.","journal-title":"Cell Metab"},{"key":"2766_CR201","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2326-6066.CIR-21-0124","volume":"10","author":"Q Wu","year":"2022","unstructured":"Wu Q, Huang Q, Jiang Y, Sun F, Liang B, Wang J, et al. Remodeling chondroitin-6-sulfate-mediated immune exclusion enhances anti-PD-1 response in colorectal cancer with microsatellite stability. Cancer Immunol Res. 2022;10:182\u201399.","journal-title":"Cancer Immunol Res"},{"key":"2766_CR202","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ van Elsas","year":"2024","unstructured":"van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42:1032-1050.e1010.","journal-title":"Cancer Cell"},{"key":"2766_CR203","doi-asserted-by":"publisher","first-page":"142415","DOI":"10.1016\/j.ijbiomac.2025.142415","volume":"308","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Y, Fang H, Cen B, Fan Y, Li J, et al. Single-cell and spatial analyses reveal the effect of VSIG4(+)S100A10(+)TAMs on the immunosuppression of glioblastoma and anti-PD-1 immunotherapy. Int J Biol Macromol. 2025;308:142415.","journal-title":"Int J Biol Macromol"},{"key":"2766_CR204","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1016\/j.devcel.2025.04.011","volume":"60","author":"Z Ma","year":"2025","unstructured":"Ma Z, Wang Y, Wang W, Wei C, Liu Z, Li Z, et al. Targeting VSIG4(+) tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer. Dev Cell. 2025;60:2594-2610.e2595.","journal-title":"Dev Cell"},{"key":"2766_CR205","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon J, Gort-Freitas NA, Kiss M, Bolli E, Messemaker M, Siwicki M, et al. A neutrophil response linked to tumor control in immunotherapy. Cell. 2023;186:1448-1464.e1420.","journal-title":"Cell"},{"key":"2766_CR206","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20:485\u2013503.","journal-title":"Nat Rev Cancer"},{"key":"2766_CR207","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-026-02570-4","volume":"25","author":"X Chu","year":"2026","unstructured":"Chu X, Ma J, Li S, Wang M, Tian Y, Lv C. Spatiotemporal dynamics of tumor-associated neutrophils: bridging the gap between cancer progression and immunotherapy. Mol Cancer. 2026;25:36.","journal-title":"Mol Cancer"},{"key":"2766_CR208","doi-asserted-by":"publisher","first-page":"eadf6493","DOI":"10.1126\/science.adf6493","volume":"383","author":"MSF Ng","year":"2024","unstructured":"Ng MSF, Kwok I, Tan L, Shi C, Cerezo-Wallis D, Tan Y, et al. Deterministic reprogramming of neutrophils within tumors. Science. 2024;383:eadf6493.","journal-title":"Science"},{"key":"2766_CR209","doi-asserted-by":"publisher","first-page":"e07167","DOI":"10.1002\/advs.202507167","volume":"12","author":"S Liu","year":"2025","unstructured":"Liu S, Zhou Y, Li G, Zhu B, Wu F, Zhou J, et al. PLAUR(+) neutrophils drive anti-PD-1 therapy resistance in patients with hepatocellular carcinoma by shaping an immunosuppressive microenvironment. Adv Sci (Weinh). 2025;12:e07167.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR210","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-026-00949-5","author":"X Li","year":"2026","unstructured":"Li X, Shan D, Zhou L, Zuo C, Zheng L, Li J, et al. Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting. Biomark Res. 2026. https:\/\/doi.org\/10.1186\/s40364-026-00949-5.","journal-title":"Biomark Res"},{"key":"2766_CR211","doi-asserted-by":"publisher","first-page":"124012","DOI":"10.1016\/j.biomaterials.2026.124012","volume":"330","author":"L Jin","year":"2026","unstructured":"Jin L, Chen L, Xue Y, Chen K, Chen S, Wang K, et al. Spatiotemporal controls of neutrophil extracellular traps boosts neutrophils immunotherapy efficiency against solid tumors. Biomaterials. 2026;330:124012.","journal-title":"Biomaterials"},{"key":"2766_CR212","doi-asserted-by":"crossref","unstructured":"He J, Zhou Z, Cheng G, Li H, Tu J, Fan Z, et al. Neutrophil extracellular traps in the tumor microenvironment, metastasis, therapy, and beyond: advances, challenges, and perspectives. J Hematol Oncol. 2026;19:29.","DOI":"10.1186\/s13045-026-01789-4"},{"key":"2766_CR213","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","volume":"56","author":"T Taifour","year":"2023","unstructured":"Taifour T, Attalla SS, Zuo D, Gu Y, Sanguin-Gendreau V, Proud H, et al. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity. 2023;56:2755-2772.e2758.","journal-title":"Immunity"},{"key":"2766_CR214","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.ccell.2025.07.014","volume":"43","author":"D Chen","year":"2025","unstructured":"Chen D, Jin Z, Chu H, Wu Y, Bian Y, Yuan T, et al. DNASE1L3-expressing dendritic cells promote CD8(+) T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. Cancer Cell. 2025;43:1758-1775.e1758.","journal-title":"Cancer Cell"},{"key":"2766_CR215","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.1038\/s41467-024-53262-w","volume":"15","author":"K Tanoue","year":"2024","unstructured":"Tanoue K, Ohmura H, Uehara K, Ito M, Yamaguchi K, Tsuchihashi K, et al. Spatial dynamics of CD39(+)CD8(+) exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer. Nat Commun. 2024;15:9033.","journal-title":"Nat Commun"},{"key":"2766_CR216","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/bjd\/ljaf525","volume":"194","author":"M Nakamura","year":"2026","unstructured":"Nakamura M, Ogata D, Kato J, Ko YW, Hu J, Yoshimitsu M, et al. Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma. Br J Dermatol. 2026;194:888\u201398.","journal-title":"Br J Dermatol"},{"key":"2766_CR217","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang G, Zhang X, Liu G, Zhang L, Chen L, et al. Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer. Nat Commun. 2025;16:10435.","journal-title":"Nat Commun"},{"key":"2766_CR218","doi-asserted-by":"publisher","first-page":"116250","DOI":"10.1016\/j.celrep.2025.116250","volume":"44","author":"X Li","year":"2025","unstructured":"Li X, Chu X, Xu W, Yang Y, Wei T, Bo Y, et al. Integrated spatial transcriptomic profiling to dissect the cellular characteristics of tumor-associated tertiary lymphoid structures. Cell Rep. 2025;44:116250.","journal-title":"Cell Rep"},{"key":"2766_CR219","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24:629\u201346.","journal-title":"Nat Rev Cancer"},{"key":"2766_CR220","doi-asserted-by":"publisher","first-page":"e70009","DOI":"10.1002\/ctm2.70009","volume":"14","author":"G Fan","year":"2024","unstructured":"Fan G, Xie T, Tang L, Li L, Han X, Shi Y. The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer. Clin Transl Med. 2024;14:e70009.","journal-title":"Clin Transl Med"},{"key":"2766_CR221","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-024-07195-3","volume":"15","author":"G Fan","year":"2024","unstructured":"Fan G, Gao R, Xie T, Li L, Tang L, Han X, et al. DKK1+ tumor cells inhibited the infiltration of CCL19+ fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma. Cell Death Dis. 2024;15:797.","journal-title":"Cell Death Dis"},{"key":"2766_CR222","doi-asserted-by":"publisher","first-page":"1699915","DOI":"10.3389\/fimmu.2025.1699915","volume":"16","author":"D Zhang","year":"2025","unstructured":"Zhang D, Ma Y, Feng D. Mapping TAM-tumor crosstalk in glioma via ligand-receptor multi-omics: mechanisms of immune evasion. Front Immunol. 2025;16:1699915.","journal-title":"Front Immunol"},{"key":"2766_CR223","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.7150\/ijbs.129291","volume":"22","author":"Z Cai","year":"2026","unstructured":"Cai Z, Li Y, Zhang J, Luo S, Qiang Z, Lu Z, et al. Single-cell deciphering of the progression trajectories of the tumor ecosystem in laryngeal squamous cell carcinoma. Int J Biol Sci. 2026;22:3862\u201385.","journal-title":"Int J Biol Sci"},{"key":"2766_CR224","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12964-023-01312-z","volume":"21","author":"Z Cai","year":"2023","unstructured":"Cai Z, Chen L, Chen S, Fang R, Chen X, Lei W. Single-cell RNA sequencing reveals pro-invasive cancer-associated fibroblasts in hypopharyngeal squamous cell carcinoma. Cell Commun Signal. 2023;21:292.","journal-title":"Cell Commun Signal"},{"key":"2766_CR225","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12943-024-02113-9","volume":"23","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Li Y, Zhao H. Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective. Mol Cancer. 2024;23:202.","journal-title":"Mol Cancer"},{"key":"2766_CR226","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/med.22010","volume":"44","author":"N Berrell","year":"2024","unstructured":"Berrell N, Sadeghirad H, Blick T, Bidgood C, Leggatt GR, O\u2019Byrne K, et al. Metabolomics at the tumor microenvironment interface: decoding cellular conversations. Med Res Rev. 2024;44:1121\u201346.","journal-title":"Med Res Rev"},{"key":"2766_CR227","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210693","author":"X Chen","year":"2022","unstructured":"Chen X, Zhao J, Herjan T, Hong L, Liao Y, Liu C, et al. IL-17-induced HIF1\u03b1 drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion. J Exp Med. 2022. https:\/\/doi.org\/10.1084\/jem.20210693.","journal-title":"J Exp Med"},{"key":"2766_CR228","first-page":"3930","volume":"118","author":"P Sonveaux","year":"2008","unstructured":"Sonveaux P, V\u00e9gran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118:3930\u201342.","journal-title":"J Clin Invest"},{"key":"2766_CR229","doi-asserted-by":"publisher","first-page":"e2505789122","DOI":"10.1073\/pnas.2505789122","volume":"122","author":"P Chen","year":"2025","unstructured":"Chen P, Geng H, Ma B, Zhang Y, Zhu Z, Li M, et al. Integrating spatial omics and single-cell mass spectrometry imaging reveals tumor-host metabolic interplay in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2025;122:e2505789122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2766_CR230","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.labinv.2025.104250","volume":"105","author":"A Mantrana","year":"2025","unstructured":"Mantrana A, S\u00e1nchez-Montero MT, Navarrete-Sirvent C, Herrera-Casanova N, Mena-Osuna R, Rivas-Crespo A, et al. Glycolysis inhibition restores immune sensitivity in GSNOR-deficient colorectal cancer. Lab Invest. 2025;105:104250.","journal-title":"Lab Invest"},{"key":"2766_CR231","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41388-026-03737-5","volume":"45","author":"X Wei","year":"2026","unstructured":"Wei X, Li X, Pan Y, Zhang Y, Zhong D, Kong W, et al. LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer. Oncogene. 2026;45:1544\u201356.","journal-title":"Oncogene"},{"key":"2766_CR232","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41746-025-02286-7","volume":"9","author":"Y Tan","year":"2025","unstructured":"Tan Y, Tan W, Liang Y, Long Y, Chen S, Hu Q, et al. Machine learning-enabled spatial multi-omics uncovers lactate-driven targets and tumor microenvironmental reprogramming in cancer. NPJ Digit Med. 2025;9:109.","journal-title":"NPJ Digit Med"},{"key":"2766_CR233","doi-asserted-by":"crossref","unstructured":"Xu W, Zhao Y, Weng J, Yu M, Yu Q, Xie P, et al. Galectin-4 drives anti-PD-L1\/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. Gut. 2025:336374.","DOI":"10.1136\/gutjnl-2025-336374"},{"key":"2766_CR234","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coph.2016.06.009","volume":"29","author":"SM Hatfield","year":"2016","unstructured":"Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1\u03b1 driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol. 2016;29:90\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"2766_CR235","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"GG Yegutkin","year":"2022","unstructured":"Yegutkin GG, Boison D. ATP and adenosine metabolism in cancer: exploitation for therapeutic gain. Pharmacol Rev. 2022;74:797\u2013822.","journal-title":"Pharmacol Rev"},{"key":"2766_CR236","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44.","journal-title":"Mol Cancer"},{"issue":"1","key":"2766_CR237","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12951-025-03500-0","volume":"23","author":"L Jiang","year":"2025","unstructured":"Jiang L, Wu T, Qu X, Li S, Jiang Q, Ren T, et al. Targeting CD39 boosts PD-1 blockade antitumor therapeutic efficacy via strengthening CD8\u2009+\u2009TILs function and recruiting B cells in cervical cancer. J Nanobiotechnol. 2025;23(1):413.","journal-title":"J Nanobiotechnol"},{"key":"2766_CR238","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","volume":"6","author":"SB Willingham","year":"2018","unstructured":"Willingham SB, Ho PY, Hotson A, Hill C, Piccione EC, Hsieh J, et al. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models. Cancer Immunol Res. 2018;6:1136\u201349.","journal-title":"Cancer Immunol Res"},{"key":"2766_CR239","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19:5626\u201335.","journal-title":"Clin Cancer Res"},{"key":"2766_CR240","doi-asserted-by":"crossref","unstructured":"Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, et al. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight. 2022;7:e142843.","DOI":"10.1172\/jci.insight.142843"},{"key":"2766_CR241","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","volume":"23","author":"J Yan","year":"2024","unstructured":"Yan J, Chen D, Ye Z, Zhu X, Li X, Jiao H, et al. Molecular mechanisms and therapeutic significance of tryptophan metabolism and signaling in cancer. Mol Cancer. 2024;23:241.","journal-title":"Mol Cancer"},{"key":"2766_CR242","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","volume":"43","author":"Z Tang","year":"2025","unstructured":"Tang Z, Bai Y, Fang Q, Yuan Y, Zeng Q, Chen S, et al. Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. Cancer Cell. 2025;43:1025-1044.e1014.","journal-title":"Cancer Cell"},{"key":"2766_CR243","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","volume":"110","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461.","journal-title":"Cancer Treat Rev"},{"key":"2766_CR244","doi-asserted-by":"publisher","first-page":"812822","DOI":"10.3389\/fimmu.2022.812822","volume":"13","author":"M Sievil\u00e4inen","year":"2022","unstructured":"Sievil\u00e4inen M, Saavalainen J, Adnan-Awad S, Salo T, Al-Samadi A. IDO1 inhibition reduces immune cell exclusion through inducing cell migration while PD-1 blockage increases IL-6 and -8 secretion from T cells in head and neck cancer. Front Immunol. 2022;13:812822.","journal-title":"Front Immunol"},{"key":"2766_CR245","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cmet.2018.07.009","volume":"28","author":"C Ecker","year":"2018","unstructured":"Ecker C, Riley JL. Translating in vitro T cell metabolic findings to in vivo tumor models of nutrient competition. Cell Metab. 2018;28:190\u20135.","journal-title":"Cell Metab"},{"key":"2766_CR246","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1158\/0008-5472.CAN-24-3039","volume":"84","author":"EJ Tyler","year":"2024","unstructured":"Tyler EJ, Pearce OMT. Tumor\u2019s digest: macrophage metabolism creates a barrier to T cells. Cancer Res. 2024;84:3322\u20133.","journal-title":"Cancer Res"},{"key":"2766_CR247","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7150\/ijbs.121356","volume":"22","author":"J Ai","year":"2026","unstructured":"Ai J, Li H, Zhang M, Liu J, Liu L, Sun C. Mechanical microenvironment in tumor immune evasion: bidirectional regulation between matrix stiffness and immune cells and its therapeutic implications. Int J Biol Sci. 2026;22:280\u2013307.","journal-title":"Int J Biol Sci"},{"key":"2766_CR248","doi-asserted-by":"crossref","unstructured":"Song M, Wang X, Liang J, Wang L, Cai J, Zhang B. The CXCL12-CXCR4\/CXCR7 axis as a therapeutic target in liver cancer: Enhancing immune evasion and the future of combination therapies. Int J Cancer. 2026;158:3065\u201379.","DOI":"10.1002\/ijc.70395"},{"key":"2766_CR249","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/1471-2407-12-615","volume":"12","author":"U Petrausch","year":"2012","unstructured":"Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012;12:615.","journal-title":"BMC Cancer"},{"key":"2766_CR250","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1038\/s41467-020-18636-w","volume":"11","author":"HM Kocher","year":"2020","unstructured":"Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun. 2020;11:4841.","journal-title":"Nat Commun"},{"key":"2766_CR251","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1001\/jama.2019.2402","volume":"321","author":"K Ng","year":"2019","unstructured":"Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, et al. Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE randomized clinical trial. JAMA. 2019;321:1370\u20139.","journal-title":"JAMA"},{"key":"2766_CR252","doi-asserted-by":"publisher","first-page":"175883592513493","DOI":"10.1177\/17588359251349321","volume":"17","author":"JSW Borgers","year":"2025","unstructured":"Borgers JSW, Medina TM, Robinson WA, Couts KL, Katsnelson EN, Muckle CM, et al. Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. Ther Adv Med Oncol. 2025;17:17588359251349320.","journal-title":"Ther Adv Med Oncol"},{"key":"2766_CR253","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","volume":"23","author":"E Nadal","year":"2023","unstructured":"Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, et al. A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023;23:708.","journal-title":"BMC Cancer"},{"key":"2766_CR254","doi-asserted-by":"crossref","unstructured":"Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, et al. Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021;9:e002068.","DOI":"10.1136\/jitc-2020-002068"},{"key":"2766_CR255","doi-asserted-by":"crossref","unstructured":"Garcia-Carbonero R, Bazan-Peregrino M, Gil-Mart\u00edn M, \u00c1lvarez R, Macarulla T, Riesco-Martinez MC, et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. 2022;10:e003255.","DOI":"10.1136\/jitc-2021-003255"},{"key":"2766_CR256","doi-asserted-by":"crossref","unstructured":"Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, et al. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J Immunother Cancer. 2021;9:e003580.","DOI":"10.1136\/jitc-2021-003580"},{"key":"2766_CR257","doi-asserted-by":"publisher","first-page":"e90353","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE. 2014;9:e90353.","journal-title":"PLoS ONE"},{"key":"2766_CR258","doi-asserted-by":"crossref","unstructured":"Rajan A, Abdul Sater H, Rahma O, Agajanian R, Lassoued W, Mart\u00e9 JL, et al. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with advanced non-small cell lung cancer. J Immunother Cancer. 2024;12:e008480.","DOI":"10.1136\/jitc-2023-008480"},{"key":"2766_CR259","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41591-025-04157-w","volume":"32","author":"TA Yap","year":"2026","unstructured":"Yap TA, Sweis RF, Vaishampayan U, Kilari D, Gainor JF, McKean M, et al. Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026;32:992\u20131001.","journal-title":"Nat Med"},{"key":"2766_CR260","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/HEP.0000000000001054","volume":"81","author":"HY Lim","year":"2025","unstructured":"Lim HY, Heo J, Peguero JA, Ryoo BY, Decaens T, Barlesi F, et al. Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC. Hepatology. 2025;81:32\u201343.","journal-title":"Hepatology"},{"key":"2766_CR261","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","volume":"33","author":"DV Catenacci","year":"2015","unstructured":"Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33:4284\u201392.","journal-title":"J Clin Oncol"},{"key":"2766_CR262","doi-asserted-by":"crossref","unstructured":"Steeghs N, Gomez-Roca C, Korakis I, Gort E, De Winter H, Stojcheva N, et al. Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study. Nat Cancer. 2026;7:810\u201322.","DOI":"10.1038\/s43018-026-01150-1"},{"key":"2766_CR263","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","volume":"30","author":"N Steeghs","year":"2024","unstructured":"Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-S\u00f8rensen M, Robbrecht D, Tabernero J, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors. Clin Cancer Res. 2024;30:2693\u2013701.","journal-title":"Clin Cancer Res"},{"key":"2766_CR264","doi-asserted-by":"publisher","first-page":"105374","DOI":"10.1016\/j.ebiom.2024.105374","volume":"109","author":"L Verlingue","year":"2024","unstructured":"Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, et al. Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and\/or metastatic cervical squamous cell carcinoma. EBioMedicine. 2024;109:105374.","journal-title":"EBioMedicine"},{"key":"2766_CR265","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1158\/1078-0432.CCR-23-2677","volume":"30","author":"H Prenen","year":"2024","unstructured":"Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, et al. Phase II study to determine the antitumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer. Clin Cancer Res. 2024;30:2945\u201353.","journal-title":"Clin Cancer Res"},{"key":"2766_CR266","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04380-z","author":"I Melero","year":"2026","unstructured":"Melero I, Tanos T, Calvo Aller E, Qvortrup C, van Dongen M, Baraibar I, et al. Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04380-z.","journal-title":"Nat Med"},{"key":"2766_CR267","doi-asserted-by":"crossref","unstructured":"Melero I, Reis B, Rusterholz C, Epp A, Kratochwil NA, Wu C, et al. Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. Nat Cancer. 2026;7:840\u201356.","DOI":"10.1038\/s43018-026-01157-8"},{"key":"2766_CR268","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10637-018-0580-2","volume":"36","author":"H Hurwitz","year":"2018","unstructured":"Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, et al. Ruxolitinib + capecitabine in advanced\/metastatic pancreatic cancer after disease progression\/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018;36:683\u201395.","journal-title":"Invest New Drugs"},{"key":"2766_CR269","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","volume":"39","author":"C Kollmannsberger","year":"2021","unstructured":"Kollmannsberger C, Britten CD, Olszanski AJ, Walker JA, Zang W, Willard MD, et al. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Invest New Drugs. 2021;39:1613\u201323.","journal-title":"Invest New Drugs"},{"key":"2766_CR270","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S1470-2045(18)30147-5","volume":"19","author":"S Pernas","year":"2018","unstructured":"Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, et al. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol. 2018;19:812\u201324.","journal-title":"Lancet Oncol"},{"key":"2766_CR271","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.22.01994","volume":"41","author":"JE Bauman","year":"2023","unstructured":"Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, et al. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, recurrent\/metastatic head and neck cancer. J Clin Oncol. 2023;41:3851\u201362.","journal-title":"J Clin Oncol"},{"key":"2766_CR272","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/ITT.S291767","volume":"10","author":"R Bughda","year":"2021","unstructured":"Bughda R, Dimou P, D\u2019Souza RR, Klampatsa A. Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 2021;10:313\u201323.","journal-title":"Immunotargets Ther"},{"key":"2766_CR273","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, et al. Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210:1137\u201351.","journal-title":"J Exp Med"},{"key":"2766_CR274","doi-asserted-by":"publisher","first-page":"eabp9229","DOI":"10.1126\/scitranslmed.abp9229","volume":"15","author":"I Melero","year":"2023","unstructured":"Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, et al. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15:eabp9229.","journal-title":"Sci Transl Med"},{"key":"2766_CR275","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40265-026-02305-1","volume":"86","author":"SJ Keam","year":"2026","unstructured":"Keam SJ. Retlirafusp alfa: first approval. Drugs. 2026;86:769\u201375.","journal-title":"Drugs"},{"key":"2766_CR276","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","volume":"17","author":"P Zhang","year":"2024","unstructured":"Zhang P, Yue L, Leng Q, Chang C, Gan C, Ye T, et al. Targeting FGFR for cancer therapy. J Hematol Oncol. 2024;17:39.","journal-title":"J Hematol Oncol"},{"key":"2766_CR277","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"2766_CR278","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961\u201371.","journal-title":"N Engl J Med"},{"key":"2766_CR279","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339.","journal-title":"N Engl J Med"},{"key":"2766_CR280","doi-asserted-by":"publisher","first-page":"45052","DOI":"10.31083\/FBL45052","volume":"30","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang W, Liu G, Wang L, Zhang X, Mei J, et al. Collagen and its roles in the tumor immune microenvironment: structure, function, and therapeutic potential. Front Biosci (Landmark Ed). 2025;30:45052.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2766_CR281","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14:1375\u201388.","journal-title":"Cancer Discov"},{"key":"2766_CR282","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-021-02070-x","volume":"40","author":"L Morosi","year":"2021","unstructured":"Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, et al. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res. 2021;40:286.","journal-title":"J Exp Clin Cancer Res"},{"key":"2766_CR283","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38:3185\u201394.","journal-title":"J Clin Oncol"},{"key":"2766_CR284","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.molmed.2023.11.002","volume":"30","author":"AH Cleveland","year":"2024","unstructured":"Cleveland AH, Fan Y. Reprogramming endothelial cells to empower cancer immunotherapy. Trends Mol Med. 2024;30:126\u201335.","journal-title":"Trends Mol Med"},{"key":"2766_CR285","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ccell.2022.08.014","volume":"40","author":"A Chryplewicz","year":"2022","unstructured":"Chryplewicz A, Scotton J, Tichet M, Zomer A, Shchors K, Joyce JA, et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell. 2022;40:1111-1127.e1119.","journal-title":"Cancer Cell"},{"key":"2766_CR286","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-23-3987","volume":"84","author":"H Wang","year":"2024","unstructured":"Wang H, Chen J, Chen X, Liu Y, Wang J, Meng Q, et al. Cancer-associated fibroblasts expressing sulfatase 1 facilitate VEGFA-dependent microenvironmental remodeling to support colorectal cancer. Cancer Res. 2024;84:3371\u201387.","journal-title":"Cancer Res"},{"key":"2766_CR287","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72:1758\u201373.","journal-title":"Gut"},{"key":"2766_CR288","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","author":"X Dong","year":"2023","unstructured":"Dong X, Ren J, Amoozgar Z, Lee S, Datta M, Roberge S, et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005583.","journal-title":"J Immunother Cancer"},{"key":"2766_CR289","doi-asserted-by":"publisher","first-page":"e2522634122","DOI":"10.1073\/pnas.2522634122","volume":"122","author":"AG Hadjigeorgiou","year":"2025","unstructured":"Hadjigeorgiou AG, Munn LL, Stylianopoulos T, Jain RK. Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors. Proc Natl Acad Sci U S A. 2025;122:e2522634122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2766_CR290","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41467-026-68865-8","volume":"17","author":"S Lu","year":"2026","unstructured":"Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, et al. NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss. Nat Commun. 2026;17:1148.","journal-title":"Nat Commun"},{"key":"2766_CR291","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22:476\u201395.","journal-title":"Nat Rev Drug Discov"},{"key":"2766_CR292","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.apsb.2022.02.014","volume":"12","author":"Y Shan","year":"2022","unstructured":"Shan Y, Ni Q, Zhang Q, Zhang M, Wei B, Cheng L, et al. Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment. Acta Pharm Sin B. 2022;12:1825\u201339.","journal-title":"Acta Pharm Sin B"},{"key":"2766_CR293","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel M, O\u2019Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38:800\u201311.","journal-title":"Invest New Drugs"},{"key":"2766_CR294","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","volume":"10","author":"I Brana","year":"2015","unstructured":"Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, et al. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015;10:111\u201323.","journal-title":"Target Oncol"},{"key":"2766_CR295","doi-asserted-by":"crossref","unstructured":"Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade. J Immunother Cancer. 2022;10:e004076.","DOI":"10.1136\/jitc-2021-004076"},{"key":"2766_CR296","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","volume":"30","author":"CA Gomez-Roca","year":"2019","unstructured":"Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D\u2019Angelo SP, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30:1381\u201392.","journal-title":"Ann Oncol"},{"key":"2766_CR297","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27:2190\u20139.","journal-title":"Clin Cancer Res"},{"key":"2766_CR298","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","volume":"26","author":"AK Nowak","year":"2015","unstructured":"Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483\u201390.","journal-title":"Ann Oncol"},{"key":"2766_CR299","doi-asserted-by":"publisher","first-page":"e23033","DOI":"10.4161\/onci.23033","volume":"2","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2:e23033.","journal-title":"Oncoimmunology"},{"key":"2766_CR300","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"2766_CR301","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.ymthe.2025.03.024","volume":"33","author":"R Jiang","year":"2025","unstructured":"Jiang R, Yang L, Liu X, Xu Y, Han L, Chen Y, et al. Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC. Mol Ther. 2025;33:3339\u201359.","journal-title":"Mol Ther"},{"key":"2766_CR302","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2022.03.017","volume":"167","author":"GM Haag","year":"2022","unstructured":"Haag GM, Springfeld C, Gr\u00fcn B, Apostolidis L, Zsch\u00e4bitz S, Dietrich M, et al. Pembrolizumab and maraviroc in refractory mismatch repair proficient\/microsatellite-stable metastatic colorectal cancer - the PICCASSO phase I trial. Eur J Cancer. 2022;167:112\u201322.","journal-title":"Eur J Cancer"},{"key":"2766_CR303","doi-asserted-by":"crossref","unstructured":"Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer. 2020;8:e001153.","DOI":"10.1136\/jitc-2020-001153"},{"key":"2766_CR304","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10637-024-01419-1","volume":"42","author":"KE Beckermann","year":"2024","unstructured":"Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, et al. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024;42:179\u201384.","journal-title":"Invest New Drugs"},{"key":"2766_CR305","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1158\/1078-0432.CCR-23-0798","volume":"29","author":"A Drakaki","year":"2023","unstructured":"Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, et al. Atezolizumab plus magrolimab, niraparib, or tocilizumab versus atezolizumab monotherapy in platinum-refractory metastatic urothelial carcinoma: a phase Ib\/II open-label, multicenter, randomized umbrella study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023;29:4373\u201384.","journal-title":"Clin Cancer Res"},{"key":"2766_CR306","doi-asserted-by":"crossref","unstructured":"Adams S, Demaria S, Rinchai D, Wang E, Novik Y, Oratz R, et al. Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer. J Immunother Cancer. 2025;13:e011173.","DOI":"10.1136\/jitc-2024-011173"},{"key":"2766_CR307","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, et al. Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin Cancer Res. 2023;29:2210\u20139.","journal-title":"Clin Cancer Res"},{"key":"2766_CR308","doi-asserted-by":"crossref","unstructured":"O'Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024;12:e009160.","DOI":"10.1136\/jitc-2024-009160"},{"key":"2766_CR309","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1158\/1078-0432.CCR-22-2041","volume":"29","author":"A Sathe","year":"2023","unstructured":"Sathe A, Mason K, Grimes SM, Zhou Z, Lau BT, Bai X, et al. Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts. Clin Cancer Res. 2023;29:244\u201360.","journal-title":"Clin Cancer Res"},{"key":"2766_CR310","doi-asserted-by":"publisher","first-page":"e1090075","DOI":"10.1080\/2162402X.2015.1090075","volume":"5","author":"DK Chang","year":"2016","unstructured":"Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, et al. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016;5:e1090075.","journal-title":"Oncoimmunology"},{"key":"2766_CR311","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1158\/1535-7163.MCT-12-0278","volume":"11","author":"DK Chang","year":"2012","unstructured":"Chang DK, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012;11:2451\u201361.","journal-title":"Mol Cancer Ther"},{"key":"2766_CR312","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003731","author":"S Maeda","year":"2022","unstructured":"Maeda S, Motegi T, Iio A, Kaji K, Goto-Koshino Y, Eto S, et al. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003731.","journal-title":"J Immunother Cancer"},{"key":"2766_CR313","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 2016;4:869\u201380.","journal-title":"Cancer Immunol Res"},{"key":"2766_CR314","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, et al. Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin Cancer Res. 2023;29:1209\u201319.","journal-title":"Clin Cancer Res"},{"key":"2766_CR315","doi-asserted-by":"publisher","first-page":"e2109432","DOI":"10.1002\/adma.202109432","volume":"34","author":"M Mamuti","year":"2022","unstructured":"Mamuti M, Wang Y, Zhao YD, Wang JQ, Wang J, Fan YL, et al. A polyvalent peptide CD40 nanoagonist for targeted modulation of dendritic cells and amplified cancer immunotherapy. Adv Mater. 2022;34:e2109432.","journal-title":"Adv Mater"},{"key":"2766_CR316","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30:966\u201379.","journal-title":"Cell Res"},{"key":"2766_CR317","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/gutjnl-2022-328697","volume":"72","author":"GS Kinker","year":"2023","unstructured":"Kinker GS, Vitiello GAF, Diniz AB, Cabral-Piccin MP, Pereira PHB, Carvalho MLR, et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut. 2023;72:1927\u201341.","journal-title":"Gut"},{"key":"2766_CR318","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42:1370-1385.e1379.","journal-title":"Cancer Cell"},{"key":"2766_CR319","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-025-01754-7","volume":"18","author":"S Deng","year":"2025","unstructured":"Deng S, Chen Y, Song B, Wang H, Huang S, Wu K, et al. Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities. J Hematol Oncol. 2025;18:97.","journal-title":"J Hematol Oncol"},{"key":"2766_CR320","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","volume":"43","author":"JC Osorio","year":"2025","unstructured":"Osorio JC, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M, et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 2025;43:1902-1916.e1909.","journal-title":"Cancer Cell"},{"key":"2766_CR321","doi-asserted-by":"publisher","first-page":"1672312","DOI":"10.3389\/fimmu.2025.1672312","volume":"16","author":"A Vall\u00e9e","year":"2025","unstructured":"Vall\u00e9e A, Drezet A, Arutkin M. Pan-cancer convergence of tumour-immune microenvironment motifs revealed by CyTOF and imaging mass cytometry. Front Immunol. 2025;16:1672312.","journal-title":"Front Immunol"},{"key":"2766_CR322","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1016\/j.csbj.2025.11.062","volume":"27","author":"G Giuliani","year":"2025","unstructured":"Giuliani G, Chavan D, Gaddam R, Stewart WC, Li Z, Jayaprakash C, et al. Immune and non-immune cell fencing of tumor cells is a widespread and functionally relevant spatial pattern in solid cancers. Comput Struct Biotechnol J. 2025;27:5537\u201348.","journal-title":"Comput Struct Biotechnol J"},{"key":"2766_CR323","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-023-40271-4","volume":"14","author":"R Arora","year":"2023","unstructured":"Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, et al. Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun. 2023;14:5029.","journal-title":"Nat Commun"},{"key":"2766_CR324","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","volume":"43","author":"Y Liu","year":"2025","unstructured":"Liu Y, Sinjab A, Min J, Han G, Paradiso F, Zhang Y, et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell. 2025;43:905-924.e906.","journal-title":"Cancer Cell"},{"key":"2766_CR325","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.xcrm.2026.102751","volume":"7","author":"J Li","year":"2026","unstructured":"Li J, Lin P, Wang H, Tang Z, Yan X, Chen X, et al. Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Rep Med. 2026;7:102751.","journal-title":"Cell Rep Med"},{"key":"2766_CR326","doi-asserted-by":"publisher","first-page":"e70608","DOI":"10.1002\/ctm2.70608","volume":"16","author":"W Wang","year":"2026","unstructured":"Wang W, Chen Z, Huang Y, Hu Z, Zhu P, Huang Z, et al. Integrative cross-tissue and spatially resolved single-cell profiling uncovers tumour-educated inflammatory remodelling of tissue-resident macrophage ecosystem with immunotherapeutic prognostic significance in pan-cancer. Clin Transl Med. 2026;16:e70608.","journal-title":"Clin Transl Med"},{"key":"2766_CR327","doi-asserted-by":"publisher","first-page":"0002","DOI":"10.34133\/cancomm.0002","volume":"46","author":"Y Lv","year":"2026","unstructured":"Lv Y, Duan T, Song J, Liu S, Zhou Z, Ba Y, et al. The Spatiotemporal Heterogeneity of Tumor-associated stromal cells: reprogramming plasticity to unlock precision cancer immunotherapy. Cancer Commun (Lond). 2026;46:0002.","journal-title":"Cancer Commun (Lond)"},{"key":"2766_CR328","doi-asserted-by":"publisher","first-page":"107887","DOI":"10.1016\/j.oraloncology.2026.107887","volume":"175","author":"Y Xin","year":"2026","unstructured":"Xin Y, Yang L, Liu C, Li D, Liu Y, Liu Y, et al. Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma. Oral Oncol. 2026;175:107887.","journal-title":"Oral Oncol"},{"key":"2766_CR329","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s42003-025-09087-4","volume":"8","author":"SY Lee","year":"2025","unstructured":"Lee SY, Lee Y. Fibroblast TGF-\u03b2 signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance. Commun Biol. 2025;8:1730.","journal-title":"Commun Biol"},{"key":"2766_CR330","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41746-025-02179-9","volume":"9","author":"Q Wang","year":"2025","unstructured":"Wang Q, Ni Y, Lu S, Zhang B, Ji J, Cai Q, et al. Multi-dimensional omics integrated machine learning framework identifies macrophage-fibroblast-tumor co-infiltration patterns to predict prognosis in gastric cancer. NPJ Digit Med. 2025;9:10.","journal-title":"NPJ Digit Med"},{"key":"2766_CR331","doi-asserted-by":"publisher","first-page":"9701","DOI":"10.1038\/s41467-025-65783-z","volume":"16","author":"S Schallenberg","year":"2025","unstructured":"Schallenberg S, Dernbach G, Ruane S, Jurmeister P, B\u00f6hm C, Standvoss K, et al. AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer. Nat Commun. 2025;16:9701.","journal-title":"Nat Commun"},{"key":"2766_CR332","doi-asserted-by":"publisher","first-page":"e2303752","DOI":"10.1002\/advs.202303752","volume":"11","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the nucleus pulposus progenitor cells via spatial transcriptomics. Adv Sci (Weinh). 2024;11:e2303752.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR333","doi-asserted-by":"publisher","first-page":"e2406218","DOI":"10.1002\/advs.202406218","volume":"12","author":"R Shen","year":"2025","unstructured":"Shen R, Jiang Y, Liu G, Gao S, Sun H, Wu X, et al. Single-cell landscape of bronchoalveolar lavage fluid identifies specific neutrophils during septic immunosuppression. Adv Sci (Weinh). 2025;12:e2406218.","journal-title":"Adv Sci (Weinh)"},{"key":"2766_CR334","doi-asserted-by":"publisher","first-page":"101224","DOI":"10.1016\/j.drup.2025.101224","volume":"81","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhou Q, Li Z, Huang F, Mo K, Shen C, et al. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal \u03b2-oxidation in hepatocellular carcinoma. Drug Resist Updat. 2025;81:101224.","journal-title":"Drug Resist Updat"},{"key":"2766_CR335","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1038\/s41467-024-50308-x","volume":"15","author":"H Li","year":"2024","unstructured":"Li H, Lin Y, He W, Han W, Xu X, Xu C, et al. SANTO: a coarse-to-fine alignment and stitching method for spatial omics. Nat Commun. 2024;15:6048.","journal-title":"Nat Commun"},{"key":"2766_CR336","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.drup.2024.101114","volume":"76","author":"X Niu","year":"2024","unstructured":"Niu X, Liu W, Zhang Y, Liu J, Zhang J, Li B, et al. Cancer plasticity in therapy resistance: mechanisms and novel strategies. Drug Resist Updat. 2024;76:101114.","journal-title":"Drug Resist Updat"},{"key":"2766_CR337","doi-asserted-by":"publisher","first-page":"102545","DOI":"10.1016\/j.xcrm.2025.102545","volume":"7","author":"H Zhang","year":"2026","unstructured":"Zhang H, Li S, Liu C, Gongye X, Li H, Ji Y, et al. Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors. Cell Rep Med. 2026;7:102545.","journal-title":"Cell Rep Med"},{"key":"2766_CR338","doi-asserted-by":"crossref","unstructured":"Zhao H, Tian H, Nuerbieke T, Ma K, Li W, Niu X, et al. Immunotherapy resistance in triple-negative breast cancer: mechanisms and emerging therapeutic strategies. Cancer Lett. 2026;658:218690.","DOI":"10.1016\/j.canlet.2026.218690"},{"key":"2766_CR339","doi-asserted-by":"publisher","first-page":"e2409668121","DOI":"10.1073\/pnas.2409668121","volume":"121","author":"Y Lauwers","year":"2024","unstructured":"Lauwers Y, De Groof TWM, Vincke C, Van Craenenbroeck J, Jumapili NA, Barthelmess RM, et al. Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer. Proc Natl Acad Sci U S A. 2024;121:e2409668121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2766_CR340","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12943-025-02443-2","volume":"24","author":"C Yang","year":"2025","unstructured":"Yang C, Li S, Wang L. Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics. Mol Cancer. 2025;24:225.","journal-title":"Mol Cancer"},{"key":"2766_CR341","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.73966","volume":"13","author":"P Dosta","year":"2023","unstructured":"Dosta P, Puigmal N, Cryer AM, Rodr\u00edguez AL, Scott E, Weissleder R, et al. Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers. Theranostics. 2023;13:1\u201315.","journal-title":"Theranostics"},{"key":"2766_CR342","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcancer.2023.04.009","volume":"93","author":"Z Wang","year":"2023","unstructured":"Wang Z, Liu Y, Niu X. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. Semin Cancer Biol. 2023;93:83\u201396.","journal-title":"Semin Cancer Biol"},{"key":"2766_CR343","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yang Y, Kong Y, Zhong B, Nakai K, Lu H. Toward graph-based decoding of tumor evolution: spatial inference of copy number variations. Diagnostics (Basel). 2025;15:3169.","DOI":"10.3390\/diagnostics15243169"},{"key":"2766_CR344","doi-asserted-by":"publisher","first-page":"189425","DOI":"10.1016\/j.bbcan.2025.189425","volume":"1880","author":"NN Chao","year":"2025","unstructured":"Chao NN, Zhang L. Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies. Biochim Biophys Acta Rev Cancer. 2025;1880:189425.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2766_CR345","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41587-025-02596-x","volume":"43","author":"C Engblom","year":"2025","unstructured":"Engblom C, Lundeberg J. Putting cancer immunotherapy into spatial context in the clinic. Nat Biotechnol. 2025;43:471\u20136.","journal-title":"Nat Biotechnol"},{"key":"2766_CR346","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","volume":"76","author":"JJ Morton","year":"2016","unstructured":"Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 2016;76:6153\u20138.","journal-title":"Cancer Res"},{"key":"2766_CR347","doi-asserted-by":"crossref","unstructured":"Chen A, Neuwirth I, Herndler-Brandstetter D. Modeling the tumor microenvironment and cancer immunotherapy in next-generation humanized mice. Cancers (Basel). 2023;15:2989.","DOI":"10.3390\/cancers15112989"},{"key":"2766_CR348","doi-asserted-by":"publisher","first-page":"1732079","DOI":"10.3389\/fimmu.2026.1732079","volume":"17","author":"X Wang","year":"2026","unstructured":"Wang X, Xiong D, Cui S, Duan B, Ding G, Huang Y, et al. Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation. Front Immunol. 2026;17:1732079.","journal-title":"Front Immunol"},{"key":"2766_CR349","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","volume":"25","author":"M Pirouzbakht","year":"2025","unstructured":"Pirouzbakht M, Hamzeh S, Soleimani Samarkhazan H. Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers. Clin Exp Med. 2025;25:355.","journal-title":"Clin Exp Med"},{"key":"2766_CR350","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.csbj.2024.09.030","volume":"23","author":"J Wu","year":"2024","unstructured":"Wu J, Koelzer VH. Towards generative digital twins in biomedical research. Comput Struct Biotechnol J. 2024;23:3481\u20138.","journal-title":"Comput Struct Biotechnol J"},{"key":"2766_CR351","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2026.01.002","volume":"119","author":"M McKenzie","year":"2026","unstructured":"McKenzie M, Irac SE, Chen Z, Moradi A, Jenner A, Nguyen Q, et al. Integrative spatial omics and artificial intelligence: transforming cancer research with omics data and AI. Semin Cancer Biol. 2026;119:65\u201382.","journal-title":"Semin Cancer Biol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02766-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02766-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02766-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:02:26Z","timestamp":1789567346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02766-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":351,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02766-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}